PPIA and colitis: Upon DSS administration, CypA could function as a chemoattractant for both innate and adaptive immune effectors [10,11,32], potentially enhancing their infiltration into the inflamed intestine and exacerbating colitis severity, characterized by significant crypt loss and inflammation.